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Introduction: As the population ages, increasing prevalence of neurodegenerative
diseases will have profound implications for the health care system. Recognizing visual
symptoms from neurodegenerative diseases can be challenging, especially in the
presence of co-existing eye diseases.
Methods: A seven-question survey was completed by attendees at the
“neurodegenerative diseases in neuro-ophthalmology” symposium during the 2017
North American Neuro-ophthalmology Society annual meeting using a web-based
audience response system. Content included demographics, patient prevalence, and
perceived barriers.
Results: Fifty-five practicing neuro-ophthalmologists (thirty-three
ophthalmology-trained, twenty-two neurology-trained) participated in the survey.
Twenty (36%) had <5 years of experience, and 19 (32%) had >15 years of experience.
Forty-one (75%) reported seeing patients more than five half-day/week. Thirty (55%)
reported that at least 1 of 10 or 1 of 20 new patients referred have a prior diagnosis of a
neurodegenerative disease. Twenty-one (40%) of the respondents reported attributing
visual complaints to higher order effects in at least 25% of patients with a prior diagnosis
of neurodegenerative disease vs. five (9%) without a prior diagnosis. For those diagnosed
with neurodegenerative disease by the neuro-ophthalmologist, reasons for referral were
unknown cause of visual symptom (56%), to confirm diagnosis and/or treat visual
complaint due to neurodegeneration (29%), and functional disorder (5%). Perceived
barriers to diagnosing visual dysfunction due to neurodegenerative disease included
difficulty making a referral to neuropsychologists or behavioral neurologists (73%), lack
of time for in-depth assessment (62%), lack of tools to assess visual dysfunction due to
neurodegenerative disease (40%), and lack of knowledge about presenting signs and
symptoms (31%).
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Conclusion: Visual symptoms from neurodegenerative disease in patients with
and without prior diagnoses of neurodegenerative disease are evaluated by
neuro-ophthalmologists. Lack of time, resources, and knowledge are barriers to
diagnosis. A larger study is warranted to guide programs to improve diagnosis of visual
consequences of neurodegenerative disease.
Keywords: higher cortical dysfunction, visual symptoms, neurodegenerative diseases, Alzheimer’s disease (AD),
posterior cortical atrophy (PCA)
INTRODUCTION
As the population ages, the increasing prevalence of age-related
neurodegenerative diseases will have profound implications
for health care systems (1). More than 5.5 million people
in the United States have Alzheimer’s disease and over
1 million have Parkinson’s disease (2). Globally, there are
almost 46 million people living with dementia. This number
is expected to rise to 131.5 million by 2050 (3). WHO
Global Burden of disease data shows that dementia is the
second largest contributor for total number of years living
with disability in people aged 60 years or older at 13.5%
comparing to heart disease (4.0%), stroke (4.4%), and cancer
(2.2%) (4).
Visual symptoms can present as early signs of
neurodegenerative disease and, therefore, are relevant to
both diagnosis of neurodegenerative disease and symptom
management. For example, posterior cortical atrophy (PCA) is
a neurodegenerative syndrome with prominent cortical visual
dysfunction with early relative sparing of memory and other
cognitive domains that is most commonly associated with
Alzheimer’s disease (AD) pathology (5).
In this issue, Olds et al. describe the largest retrospective
dataset regarding symptoms and signs in patients with PCA
presenting to neuro-ophthalmology (6). Data were collected
using a retrospective chart review to characterize each patient’s
history, examination, evaluation, and treatment. Data were
also compared to previously published PCA cohorts and on
previously published expert opinion regarding the presentation
of PCA by cognitive specialists. From a total of 38 patients
from 11 institutions and community practices, the PCA cohort
presenting to neuro-ophthalmologists had an older age of
presentation (68 years) and more likely to be female (3:1) and
report difficulty reading (91%) at presentation compared to
published data and surveys. Furthermore, poor performance on
color vision testing (88%), stereopsis (86%), and visual field
testing (89%) were the most common findings on examination
and are less likely to be assessed by the cognitive specialist. The
results of this survey highlight the importance of considering
PCA in older adults who report difficulty reading, have
apparent color vision defect on testing, decreased stereopsis,
and a visual field defect without explanation. In addition,
this study emphasizes the increasingly important role of the





DISEASE IN THEIR PRACTICE
To further understand the landscape and challenges faced
by neuro-ophthalmologists consulting on patients with
neurodegenerative disorders, we conducted a survey among
the attendees at the “Neurodegenerative Diseases and Neuro-
ophthalmology” symposium during the 2018 North American
Neuro-Ophthalmology Society annual meeting. Conferences
i/o web-based audience response system was used to conduct
the survey. All participants agreed to anonymous extraction of
their survey responses for this project. This study was approved
by the Institutional Review Board of Stanford University. The
seven-question survey included provider demographics, patient
prevalence, and perceived barriers.
A total of 69 attendees participated in the survey. Among
them, 55 were practicing neuro-ophthalmologists and 14 were
non-neuro-ophthalmologists or trainees. Responses from 55
practicing neuro-ophthalmologists (33 ophthalmology-trained,
22 neurology-trained) were analyzed (Table 1). Twenty (36%)
had <5 years of experience, and 19 (32%) had >15 years of
experience. Forty-one (75%) reported seeing patients more than
five half days per week.
Thirty (55%) of the respondents reported that at least 5–
10% of new patients referred to them had a prior diagnosis
of a neurodegenerative disease, suggesting that these patients
are not uncommon in neuro-ophthalmic practice. Twenty-one
(40%) reported attributing visual complaints to higher order
effects in more than 25% of patients with a prior diagnosis of
neurodegenerative disease. The extrapolated prevalence of higher
order visual dysfunction with pre-existing neurodegenerative
disorder was 302–6,314/100,000, which would be ∼1/3–1/2
of all patients with Alzheimer’s disease (10,000 per 100,000)
if all patients with neurodegenerative disease were to harbor
AD. This is similar to the prevalence reported in a very large
AD Neuroimaging Initiative Dataset, where Woodward et al.
(7) reported cognitive testing with visuospatial worse than
memory by >2 SD in 35% mild cognitive impairment and 50%
of AD patients. Our survey data is striking with regards to
the prevalence of non-neurodegenerative disease related visual
symptoms that reaches>90%, many of which might have proven
treatment strategies.
Frontiers in Neurology | www.frontiersin.org 2 July 2020 | Volume 11 | Article 679
Liu et al. Visual Symptoms in Neurodegenerative Diseases
TABLE 1 | Summary of survey data on visual symptoms in neurodegenerative diseases.
Total n = 55 Neurology trained
n = 22, 40%
Ophthalmology








































Frequency of seeing new patients with a prior diagnosis of neurodegenerative disease
1 in every 5–10 patients
1 in every 11–20 patients
1 in every 21–30 patients













Percentage of patients referred for visual complaints and neurodegenerative diseases

















Frequency of suspicion for neurodegenerative diseases as the cause for visual complaints in
patients without a prior diagnosis of neurodegenerative disease
1 in every 5–10 patients
1 in every 11–20 patients
1 in every 21–30 patients













For patients diagnosed with neurodegenerative disease by a neuro-ophthalmologist, the most
common reasons for referral were
Could not find other causes
No other appropriate providers
For formal diagnosis and treatment

















Barriers to diagnosing visual dysfunction due to neurodegenerative disease
Difficulty referring to neuropsychologists
Lack of knowledge


















For new patients without a prior diagnosis of
neurodegenerative disease, 10 (19%) respondents reported
attributing visual complaints to undiagnosed neurodegenerative
disease in more than 5% of patients. For these patients diagnosed
with neurodegenerative disease by the neuro-ophthalmologist,
reasons for referral included unknown cause of visual symptom
(56%), to confirm diagnosis and/or treat visual complaint
due to neurodegeneration (29%), and functional neurological
symptom disorder (5%). These data reinforce the important
role of experts who can distinguish neurodegenerative from
non-neurodegenerative-related visual symptoms.
In our survey, barriers perceived by neuro-ophthalmologists
to diagnosing visual dysfunction due to neurodegenerative
disease were multifactorial and included: (1) difficulty making a
referral to neuropsychologists or behavioral neurologists (73%),
(2) lack of time for in-depth assessment (62%), (3) lack of tools
to assess visual dysfunction due to neurodegenerative disease
(40%), and (4) lack of knowledge about presenting signs and
symptoms (31%). Both neurology-trained and ophthalmology-
trained neuro-ophthalmologists perceived lack of time in clinic
as a common barrier to diagnosing visual dysfunction due to
neurodegenerative disease. More ophthalmology trained neuro-
ophthalmologists identified lack of knowledge, difficulty referring
to neuropsychologist, and lack of tools in clinic as barriers than
neurology-trained neuro-ophthalmologists.
DISCUSSION
Recognizing visual symptoms from neurodegenerative diseases
can be challenging, especially in the presence of co-existent
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eye conditions. Though our survey is limited by selection
bias of those who chose to attend a “Neurogenerative
Diseases and Neuro-ophthalmology Symposium” and those
who agreed to participate, the data collected highlight the
role neuro-ophthalmologists are playing in distinguishing
visual symptoms from neuro-degenerative and non-
neurodegenerative causes for the purposes of diagnosis and
treatment as the population continues to age. They also
highlight need for education of referring providers and neuro-
ophthalmologists to optimize diagnosis and care. Evaluation of
visual function in patients with neurodegenerative disorders
can be challenging, but familiarity with the type of visual
dysfunction most commonly associated with each disorder
will allow for identification, focused assessment, and treatment
when possible.
Though currently no disease-modifying treatment exists for
most neurodegenerative diseases that lead to dementia, early
diagnosis, and prompt intervention for visual dysfunction, be
they related to neurodegenerative disease or not, can improve
quality of life. The data published by Olds et al. regarding
the presentation of Posterior Cortical Atrophy syndrome
to neuro-ophthalmologists (6) and our survey of neuro-
ophthalmology practice trends related to neurodegenerative
disease raise important points regarding how assessment
and care might be improved for these patients, as neuro-
ophthalmologists are frequently positioned to be the
definitive diagnostician for patients presenting with higher
order visual dysfunction. A larger study is warranted to
further characterize barriers to diagnosis and treatment and
develop interventions to decrease the obstacles associated
with diagnosis and care, in order to guide patient and
caregiver education and support, advocacy, and informed
policy making.
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